Delivery of Dual Drug Loaded Lipid Based Nanoparticles across the Blood–Brain Barrier Impart Enhanced Neuroprotection in a Rotenone Induced Mouse Model of Parkinson’s Disease

Kundu, Paromita; Das, Manasi; Tripathy, Kalpalata; Sahoo, Sanjeeb K.

doi:10.1021/acschemneuro.6b00207

Cited by 128 publications

(66 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study used lipid-based nanoparticles (curcumin and piperine coloaded glyceryl monooleate nanoparticles). In vivo studies revealed that formulated dual drug (curcumin and piperine) loaded nanoparticles were able to cross the BBB, which rescued rotenone-induced motor coordination impairment, and restrained dopaminergic neuronal degeneration in a PD mouse model [116]. …”

Section: Natural Product-based Amyloid Inhibitorsmentioning

confidence: 99%

Natural product-based amyloid inhibitors

Velander

Henderson

et al. 2017

Biochemical Pharmacology

178

135

View full text Add to dashboard Cite

Many chronic human diseases, including multiple neurodegenerative diseases, are associated with deleterious protein aggregates, also called protein amyloids. One common therapeutic strategy is to develop protein aggregation inhibitors that can slow down, prevent, or remodel toxic amyloids. Natural products are a major class of amyloid inhibitors, and several dozens of natural product-based amyloid inhibitors have been identified and characterized in recent years. These plant- or microorganism-extracted compounds have shown significant therapeutic potential from in vitro studies as well as in vivo animal tests. Despite the technical challenges of intrinsic disordered or partially unfolded amyloid proteins that are less amenable to characterizations by structural biology, a significant amount of research has been performed, yielding biochemical and pharmacological insights into how inhibitors function. This review aims to summarize recent progress in natural product-based amyloid inhibitors and to analyze their mechanisms of inhibition in vitro. Major classes of natural product inhibitors and how they were identified are described. Our analyses comprehensively address the molecular interactions between the inhibitors and relevant amyloidogenic proteins. These interactions are delineated at molecular and atomic levels, which include covalent, non-covalent, and metal-mediated mechanisms. In vivo animal studies and clinical trials have been summarized as an extension. To enhance natural product bioavailability in vivo, emerging work using nanocarriers for delivery has also been described. Finally, issues and challenges as well as future development of such inhibitors are envisioned.

show abstract

Section: Natural Product-based Amyloid Inhibitorsmentioning

confidence: 99%

Natural product-based amyloid inhibitors

Velander

Henderson

et al. 2017

Biochemical Pharmacology

178

135

View full text Add to dashboard Cite

show abstract

“…Amine-functionalized mesoporous silica nanoparticles of curcumin showed interaction with α-syn species and prevented fibrillation [374]. A nanoformulation containing curcumin and piperine with glyceryl monooleate nanoparticles has been shown to prevent α-syn oligomerization and fibrillation [375]. Another nanoformulation prepared with lactoferrin by sol-oil chemistry reduced α-syn expression in dopaminergic SK-N-SH cells treated with rotenone [376].…”

Section: Polyphenolsmentioning

confidence: 99%

Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts

et al. 2020

View full text Add to dashboard Cite

Parkinson’s Disease (PD) is characterized both by the loss of dopaminergic neurons in the substantia nigra and the presence of cytoplasmic inclusions called Lewy Bodies. These Lewy Bodies contain the aggregated α-synuclein (α-syn) protein, which has been shown to be able to propagate from cell to cell and throughout different regions in the brain. Due to its central role in the pathology and the lack of a curative treatment for PD, an increasing number of studies have aimed at targeting this protein for therapeutics. Here, we reviewed and discussed the many different approaches that have been studied to inhibit α-syn accumulation via direct and indirect targeting. These analyses have led to the generation of multiple clinical trials that are either completed or currently active. These clinical trials and the current preclinical studies must still face obstacles ahead, but give hope of finding a therapy for PD with time.

show abstract

“…And through cell experiment and animal model experiment, it proved that glyceride nanoparticles could enhance the bioavailability of piperine and other active components [30] . When piperine and curcumin embedded in glyceride nanoparticles simultaneously and adjusted the particle size less than 60nm, these nanoparticles could pass through blood brain barrier and cure parkinsonismus [31] .…”

Section: Piperine Nanoparticles Based On Polylactic Acid/glyceride Mamentioning

confidence: 99%

Advance on delivery nanocarriers of piperine: nanoparticles

Lingli¹

2019

E3S Web Conf.

View full text Add to dashboard Cite

Piperine is a kind of natural functional active components with spicy flavor and varies pharmacology effects. It has wide application in the food and medicine industries. However, the solubility of piperine is low, and it was easy to be transformed or degraded during the conditions of acid, alkali, light, heat and oxygen which lead to the vanish of its function. In order to enhance the stability of piperine, the nanotechnology was utilized to fabricate the delivery carrier of piperine. In this paper, the latest research progress of piperine nanoparticles was reviewed by summarizing domestic and foreign literature. The characteristics, preparation methods, preparation materials and stability of nanoparticle delivery carriers were systematically discussed. Finally, the present problems and future development of piperine delivery carrier were analyzed and forecasted in order to provide a reference for profound process and study of piperine.

show abstract

Delivery of Dual Drug Loaded Lipid Based Nanoparticles across the Blood–Brain Barrier Impart Enhanced Neuroprotection in a Rotenone Induced Mouse Model of Parkinson’s Disease

Cited by 128 publications

References 66 publications

Natural product-based amyloid inhibitors

Natural product-based amyloid inhibitors

Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts

Advance on delivery nanocarriers of piperine: nanoparticles

Contact Info

Product

Resources

About